Shanghai Eyes Commercial Insurance Push To Address Drug Firms’ Pricing Concerns
Policy Changes Urged
As Shanghai seeks to develop into an international biopharma hub, the local government is encouraging commercial medical insurers to cover more innovative drugs in their products. The policy aims to provide an alternative solution to dominant pricing by the national public payer, which often imposes deep discounts on novel drugs in exchange for reimbursement coverage.
You may also be interested in...
Allorion's key innovative attractions include discovery platforms for allosteric inhibitor screening and the discovery of synthetic lethality targets/molecules, along with a small but growing pipeline of novel assets. Founded in 2020, the China- and US-based biotech has now raised more than $100m in three financing deals, including a $50m series B.
The 2022 pricing negotiations for innovative drugs organized by China’s National Healthcare Security Administration have slashed prices of included products by 60% on average, a level mostly unchanged from the 2021 round, although 36% more novel medicines were covered.
The annual reimbursement price negotiations between pharma firms and China’s National Healthcare Security Administration are just around the corner. While some have chosen to walk away from the process completely, others including majors BeiGene and Hengrui are girding up for another round of potentially deep cuts.